Compare Orchid Chemicals with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs FRESENIUS KABI ONCO. - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD FRESENIUS KABI ONCO. ORCHID PHARMA LTD/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -0.4 22.1 - View Chart
P/BV x 0.1 3.1 3.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
FRESENIUS KABI ONCO.
Mar-13
ORCHID PHARMA LTD/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs194176 110.2%   
Low Rs3579 44.6%   
Sales per share (Unadj.) Rs276.537.7 733.6%  
Earnings per share (Unadj.) Rs-79.25.1 -1,555.2%  
Cash flow per share (Unadj.) Rs-43.56.7 -646.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.942.5 126.8%  
Shares outstanding (eoy) m70.45158.23 44.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.4 12.3%   
Avg P/E ratio x-1.425.0 -5.8%  
P/CF ratio (eoy) x-2.618.9 -13.9%  
Price / Book Value ratio x2.13.0 71.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,06720,135 40.1%   
No. of employees `0002.81.2 243.1%   
Total wages/salary Rs m2,527703 359.4%   
Avg. sales/employee Rs Th6,956.15,176.2 134.4%   
Avg. wages/employee Rs Th902.5610.4 147.8%   
Avg. net profit/employee Rs Th-1,993.0699.6 -284.9%   
INCOME DATA
Net Sales Rs m19,4775,963 326.6%  
Other income Rs m40718 2,262.2%   
Total revenues Rs m19,8845,981 332.5%   
Gross profit Rs m1,1031,430 77.1%  
Depreciation Rs m2,519258 976.8%   
Interest Rs m5,227-26 -20,103.1%   
Profit before tax Rs m-6,2361,216 -512.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-68 -750.4%   
Tax Rs m-125342 -36.6%   
Profit after tax Rs m-5,580806 -692.4%  
Gross profit margin %5.724.0 23.6%  
Effective tax rate %2.028.1 7.1%   
Net profit margin %-28.713.5 -212.0%  
BALANCE SHEET DATA
Current assets Rs m11,0145,102 215.9%   
Current liabilities Rs m32,0602,385 1,344.0%   
Net working cap to sales %-108.145.6 -237.2%  
Current ratio x0.32.1 16.1%  
Inventory Days Days95150 63.2%  
Debtors Days Days34113 29.6%  
Net fixed assets Rs m29,4405,148 571.9%   
Share capital Rs m705158 445.3%   
"Free" reserves Rs m2,0436,556 31.2%   
Net worth Rs m3,8006,732 56.4%   
Long term debt Rs m9,018952 947.1%   
Total assets Rs m46,51010,388 447.7%  
Interest coverage x-0.2-45.8 0.4%   
Debt to equity ratio x2.40.1 1,677.8%  
Sales to assets ratio x0.40.6 73.0%   
Return on assets %-0.87.5 -10.1%  
Return on equity %-146.912.0 -1,226.7%  
Return on capital %-3.714.6 -25.6%  
Exports to sales %37.974.5 50.9%   
Imports to sales %22.624.8 91.3%   
Exports (fob) Rs m7,3784,441 166.1%   
Imports (cif) Rs m4,4061,477 298.2%   
Fx inflow Rs m7,5135,298 141.8%   
Fx outflow Rs m5,6491,772 318.7%   
Net fx Rs m1,8653,525 52.9%   
CASH FLOW
From Operations Rs m1,6821,274 132.0%  
From Investments Rs m-9,860-1,204 818.8%  
From Financial Activity Rs m6,644-196 -3,388.0%  
Net Cashflow Rs m-1,535-126 1,215.4%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 4.6 0.3 1,533.3%  
FIIs % 3.3 9.6 34.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 9.1 607.7%  
Shareholders   84,811 42,599 199.1%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  FDC LTD.  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - GSK PHARMA COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS